Latest news with #OpticalCoherenceTomography
Korea Herald
23-05-2025
- Business
- Korea Herald
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /PRNewswire/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
India Today
21-05-2025
- Health
- India Today
High blood pressure silently damages your eyes: Know how to catch it early
One of the most common diseases that carries a high burden among the Indian population is hypertension. This non-communicable disease, which is known to show no symptoms, hence its name 'the silent killer', ends up developing into highly serious blood pressure is when the force of blood pushing against the artery wall is too high. For this, the heart has to work harder to pump no treatment is given, hypertension can damage blood vessels throughout the body. Besides leading to health problems like heart disease, stroke and kidney disease, high blood pressure can also damage your vision. "We know that high blood pressure affects the heart, but what we don't realise often is that it can silently damage the eyes and even lead to blindness if left untreated," said Dr. Jay Goyal, Eye Surgeon and Director at Surya Eye Institute. When no treatment is given, hypertension can damage blood vessels throughout the body. () 'In India, about 22.6% of the population has hypertension. This puts a large part of the population at risk for severe vision problems. Thankfully, we now have advanced, non-invasive tools like OCTA and OCT EDI that help us detect early damage in the retina and optic nerve caused by hypertension.'advertisementHOW HIGH BLOOD PRESSURE AFFECTS YOUR EYESWhen high blood pressure damages the small and delicate blood vessels that carry blood to the eyes. This can lead to:Retinopathy: This is damage to the retina, the part of the eye that senses light. It can cause blurred vision, bleeding in the eye, or complete vision loss. People with both diabetes and high blood pressure are at even higher risk. When high blood pressure damages the small and delicate blood vessels that carry blood to the eyes. () Choroidopathy: High blood pressure can lead to fluid build-up under the retina, causing distorted vision or scarring that worsens neuropathy: If blood flow to the optic nerve (which sends visual signals to the brain) is blocked, it can cause nerve damage, bleeding inside the eye, and permanent vision TO CATCH IT EARLY Since high blood pressure often shows no early symptoms, regular health check-ups are to Dr. Goyal, eye specialists now use tests like OCT (Optical Coherence Tomography) and OCTA (Optical Coherence Tomography Angiography) to detect changes in blood flow and signs of early eye damage, even before symptoms appear. Since high blood pressure often shows no early symptoms, regular health check-ups are required. (s) These tests are quick, painless, and non-invasive. Therefore, early detection is crucial. You can reduce your risk of eye damage from hypertension by:Getting your eyes checked regularly, especially if you have high blood pressureEating a balanced diet low in saltExercising regularlyManaging stressTaking prescribed medication to control your blood pressureHigh blood pressure may be silent, but its effects don't have to be. With regular screenings and a healthy lifestyle, vision loss from hypertension can often be Watch
Yahoo
19-05-2025
- Health
- Yahoo
PhotoniCare's OtoSight Demonstrates More Accurate Diagnosis and a 50 Percent Reduction in Antibiotic Usage for Pediatric Ear Infections in Large Randomized Controlled Trial
DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) -- PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances patient outcomes, is pleased to announce its progress in the diagnosis and treatment of pediatric ear infections that affect more than 80 percent of children by age three, account for millions of visits to the pediatrician each year, and are the leading cause of antibiotic use in children. The interim results from the OTO-MATIC randomized controlled trial (RCT) demonstrate PhotoniCare's OtoSight™ Middle Ear Scope significantly reduces the number of antibiotic prescriptions written for pediatric patients presenting to a primary care office with ear-related complaints as well as a shift toward more singular treatment decisions, reducing reliance on combination therapies. The multicenter, real-world effectiveness study showed a 50 percent reduction in the odds of antibiotic prescribing when clinicians used PhotoniCare's Optical Coherence Tomography (OCT) otoscope, compared to the standard of care (SOC) with a traditional otoscope. 83 percent of target recruitment was included in the interim analysis, which was sufficiently powered. The results of the study, Otitis Treatment with OtoSight™ – Modification of Antibiotic Treatment Intervention in Children (OTO-MATIC), have been published via open access in the International Journal of Pediatric Otorhinolaryngology. Commenting on the results of the study, Ryan Shelton, Ph.D., CEO and Co-Founder of PhotoniCare said, 'Ear infections are not only the most common reason children receive antibiotics—they're also a leading cause of surgery and hearing loss in pediatrics. The OtoSight Middle Ear Scope leverages OCT imaging to visualize through the eardrum and determine the presence or absence of fluid in the middle ear as well as characterize the type of fluid, even in the presence of earwax. These interim RCT results validate the power of the technology to improve diagnostic accuracy, support antibiotic stewardship, and ultimately help providers deliver better care for a condition that affects the vast majority of children.' Dr. April Zambelli-Weiner, M.P.H., President and CEO of TTi Health Research & Economics who serves as Principal Investigator and Contract Research Organization CRO for the study added, 'Our research reveals that the OtoSight device, through its advanced OCT imaging, can significantly curb unnecessary antibiotic use. It does this by providing clinicians with a clearer picture of middle ear conditions, leading to more accurate diagnoses and a 50 percent decrease in antibiotic prescriptions. It streamlines treatment approaches, encouraging single therapies over multimodal treatments. These findings, replicated across our entire study cohort, suggest a promising future for this technology in enhancing both diagnostic accuracy and antibiotic stewardship.' Children with ear-related complaints are misdiagnosed up to 50 percent of the time using the current gold standard, examination via otoscope. Children can suffer from recurring ear infections for six to 12 months before they are referred to an ENT specialist, and are often prescribed increasingly potent antibiotics during this time. Often, the endpoint of the disease is insertion of tympanostomy tubes in the eardrum. More than one million tube surgeries are performed in the U.S. alone every year. OtoSight is the first FDA cleared device for middle-ear visualization, offering unique CPT codes to capture the procedure. OtoSight has significant commercial traction, validating product-market fit in pediatrics, family practices and ENT. In addition to the current large RCT, the company has previously published multiple peer-reviewed manuscripts demonstrating the utility of the device to help drive continued reimbursement and market adoption. About PhotoniCare Founded in 2013, PhotoniCare's mission is to improve clinical outcomes and serve unmet patient and provider needs by translating novel light-based technologies into objective medical practice, starting with the OtoSight™ Middle Ear Scope. The FDA-cleared OtoSight Middle Ear Scope was developed for healthcare providers seeking a superior solution for pediatric middle ear issues. With remarkable 90+ percent reader accuracy in determining the presence or absence of fluid in the middle ear, the OtoSight Middle Ear Scope eliminates subjectivity and speculation by providing patients with a non-invasive and comprehensive assessment of middle ear fluid, even in the presence of significant earwax. PhotoniCare has been recognized by numerous organizations, winning the 2025 NextMed Health MEDy Award, 2021 Northwest Arkansas Tech Summit Pitch Competition, the 2018 MedTech Innovator Execution Award, and the 2018 AdvaMed Accel Virginia Shimer Rybski Memorial Award. The company was also a member of the 2016 Dreamit Ventures accelerator program and took first place at the 7th Annual Insight Product Development 2019 HealthTECH Startup Competition. PhotoniCare has received more than $6 million in support from the National Institutes of Health, most recently a Phase SBIR II award for work in artificial intelligence. In 2015, PhotoniCare was the winner of a grant from the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), an FDA-funded consortium led by Children's National Hospital. More information can be found at Media Contact:David Gutierrez, Dresner Corporate Services for PhotoniCare, (312) 780-7204, dgutierrez@
Cision Canada
15-05-2025
- Business
- Cision Canada
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging Français
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
Yahoo
15-05-2025
- Business
- Yahoo
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook. View original content to download multimedia: SOURCE Intalight Inc. View original content to download multimedia:
